Literature DB >> 7558342

Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections.

P L Fidel1, J L Cutright, J D Sobel.   

Abstract

Studies to date with CBA/J mice suggest a limited role for systemic cell-mediated immunity (CMI) against vaginal Candida albicans infections. The results of the present study show that preinduced Candida-specific systemic CMI was equally nonprotective against C. albicans vaginal infections in mice with high (BALB/cJ), low (DBA/2), or intermediate (CBA/J) resistance to C. albicans infections. Similarly, the locally acquired partial protection against a second C. albicans vaginal infection was equally observed with BALB/cJ, DBA/2, and CBA/J mice. These results indicate that observations made previously with CBA/J mice were not murine strain specific and provide additional support for the hypothesis that systemic CMI does not represent a dominant host defense mechanism at the vaginal mucosa.

Entities:  

Mesh:

Year:  1995        PMID: 7558342      PMCID: PMC173593          DOI: 10.1128/iai.63.10.4191-4194.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Cellular and humoral immune status in women with chronic Candida vaginitis.

Authors:  R E Syverson; H Buckley; J Gibian; G M Ryan
Journal:  Am J Obstet Gynecol       Date:  1979-07-15       Impact factor: 8.661

2.  Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus.

Authors:  L Knight; J Fletcher
Journal:  J Infect Dis       Date:  1971-04       Impact factor: 5.226

3.  Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome.

Authors:  R S Klein; C A Harris; C B Small; B Moll; M Lesser; G H Friedland
Journal:  N Engl J Med       Date:  1984-08-09       Impact factor: 91.245

4.  Candidiasis in the transplant patient.

Authors:  R A Clift
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

5.  Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

6.  Inhibition of Candida albicans--induced lymphocyte proliferation by lymphocytes and sera from women with recurrent vaginitis.

Authors:  S S Witkin; I R Yu; W J Ledger
Journal:  Am J Obstet Gynecol       Date:  1983-12-01       Impact factor: 8.661

7.  Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.

Authors:  P L Fidel; M E Lynch; D H Conaway; L Tait; J D Sobel
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

8.  Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

9.  Immune responses to Candida albicans in genetically distinct mice.

Authors:  R F Hector; J E Domer; E W Carrow
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

10.  Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis.

Authors:  P L Fidel; M E Lynch; V Redondo-Lopez; J D Sobel; R Robinson
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  14 in total

1.  Evidence for a unique expression of CD4 on murine vaginal CD4+ cells.

Authors:  F L Wormley; M Scott; W Luo; M Baker; J Chaiban; P L Fidel
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

2.  Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiasis.

Authors:  C H Little; G M Georgiou; A Marceglia; H Ogedgebe; R E Cone; D Mazza
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Resistance of T-cell receptor delta-chain-deficient mice to experimental Candida albicans vaginitis.

Authors:  F L Wormley; C Steele; K Wozniak; K Fujihashi; J R McGhee; P L Fidel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Analysis of vaginal cell populations during experimental vaginal candidiasis.

Authors:  P L Fidel; W Luo; C Steele; J Chabain; M Baker; F Wormley
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  Murine model of concurrent oral and vaginal Candida albicans colonization to study epithelial host-pathogen interactions.

Authors:  Durdana Rahman; Mukesh Mistry; Selvam Thavaraj; Stephen J Challacombe; Julian R Naglik
Journal:  Microbes Infect       Date:  2007-01-27       Impact factor: 2.700

6.  Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis.

Authors:  Junko Yano; Elizabeth Lilly; Melissa Barousse; Paul L Fidel
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

7.  An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis.

Authors:  Paul L Fidel; Melissa Barousse; Terri Espinosa; Mercedes Ficarra; Joy Sturtevant; David H Martin; Alison J Quayle; Kathleen Dunlap
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  Vaginal T lymphocyte population kinetics during experimental vaginal candidosis: evidence for a possible role of CD8+ T cells in protection against vaginal candidosis.

Authors:  M Ghaleb; M Hamad; K H Abu-Elteen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

9.  Study of Candida albicans vaginitis model in Kunming mice.

Authors:  Zhuo Chen; Xiaofeng Kong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-06

Review 10.  Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy".

Authors:  Junko Yano; Brian M Peters; Mairi C Noverr; Paul L Fidel
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.